# Protocol PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/protocol

> The FDA approved protocol, sponsored by AIM ImmunoTech Inc. (AIM), on September 30, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is protocol FDA approved?

Yes. The FDA approved protocol, sponsored by AIM ImmunoTech Inc. (AIM), on September 30, 2025. SEC Form 10-Q: "For the three months ended September 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." [Calendar and source filings](https://sec-api.dev/pdufa/protocol)

Source: SEC Form 10-Q, accession 0001493152-25-023894, https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm (retrieved 2026-11-12). Last confirmed 2025-11-17. Cite: https://sec-api.dev/pdufa/protocol#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | protocol |
| Codes | AMP-511 |
| Sponsor | AIM ImmunoTech Inc. (AIM) https://sec-api.dev/companies/aim/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001493152-24-045971): "For the three months ended September 30, 2024 and 2023, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." https://www.sec.gov/Archives/edgar/data/946644/000149315224045971/form10-q.htm

### December 31, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0001641172-25-000847): "For the years ended December 31, 2024 and 2023, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to" https://www.sec.gov/Archives/edgar/data/946644/000164117225000847/form10-k.htm

### March 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-15, last confirmed 2025-05-15.
- SEC Form 10-Q (accession 0001641172-25-011033): "For the three months ended March 31, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." https://www.sec.gov/Archives/edgar/data/946644/000164117225011033/form10-q.htm

### June 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-14, last confirmed 2025-08-14.
- SEC Form 10-Q (accession 0001493152-25-011986): "For the three months ended June 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm
- SEC Form 10-Q (accession 0001493152-25-011986): "For the six months ended June 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to" https://www.sec.gov/Archives/edgar/data/946644/000149315225011986/form10-q.htm

### September 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-17, last confirmed 2025-11-17.
- SEC Form 10-Q (accession 0001493152-25-023894): "For the three months ended September 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm
- SEC Form 10-Q (accession 0001493152-25-023894): "For the nine months ended September 30, 2025 and 2024, we had no Alferon N Injection® Finished Good product to commercially sell and all revenue was generated from the EAP and our FDA approved open-label treatment protocol, ("AMP 511"), that allows patient access to Ampligen® for treatment in an open-label safety study." https://www.sec.gov/Archives/edgar/data/946644/000149315225023894/form10-q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/protocol.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Protocol PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/protocol

```bibtex
@misc{secapidev_pdufa_protocol_20261116,
  title        = {Protocol PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/protocol}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_protocol_20261116","title":"Protocol PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/protocol","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
